The pharma and biotech industries have reached significant R&D milestones in the past decade, including the broad adoption of immunotherapy and the advent of gene therapies. Despite these breakthroughs, the productivity of research and development efforts among large pharma/biotech remains low. As novel methods of development become more commonplace and the areas of focus shift from larger disease areas to more niche diseases, pharma companies will need to expand on existing capabilities across the product lifecycle. In this paper Emre Vural, Kishore Gangangari, and Joanna Lee look at how R&D has evolved from a focus on primary care to specialty medicine for rare disease as well as innovation in R&D sourcing models.
Click the PDF below to learn more.
CRA Insights
“Changes” in sourcing R&D in pharma and biotech: The old made new again?
April 3, 2020
Upcoming events
Asembia’s AXS26 Summit
CRA is a proud supporter of the conference where attendees span the full spectrum of the pharmacy and healthcare ecosystem, bringing together key...
GAR Live: Life Sciences
CRA is a proud sponsor of the first-ever GAR Live: Life Sciences, evolving from the much-loved Technology Disputes event to reflect the growing complexity and...